Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials

TY - JOUR

T1 - Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine

T2 - a pooled post-hoc analysis of two parallel randomized trials

AU - for the ZOE-50/70 Study Group

AU - on behalf of GSK

AU - Oostvogels, Lidia

AU - Heineman, Thomas C.

AU - Johnson, Robert W.

AU - Levin, Myron J.

AU - McElhaney, Janet E.

AU - Van den Steen, Peter

AU - Zahaf, Toufik

AU - Dagnew, Alemnew F.

AU - Chlibek, Roman

AU - Diez-Domingo, Javier

AU - Gorfinkel, Iris S.

AU - Hervé, Caroline

AU - Hwang, Shinn Jang

AU - Ikematsu, Hideyuki

AU - Kalema, George

AU - Lal, Himal

AU - McNeil, Shelly A.

AU - Mrkvan, Tomas

AU - Pauksens, Karlis

AU - Smetana, Jan

AU - Watanabe, Daisuke

AU - Weckx, Lily Yin

AU - Cunningham, Anthony L.

N1 - Publisher Copyright: © 2019, © 2019 GlaxoSmithKline Biologicals SA. Published with license by Taylor & Francis Group, LLC.

PY - 2019/12/2

Y1 - 2019/12/2

KW - Varicella-zoster virus

KW - adjuvanted recombinant zoster vaccine

KW - comorbidity

KW - underlying chronic disease

KW - vaccine efficacy

KW - vaccine safety

UR - http://www.scopus.com/inward/record.url?scp=85068503513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068503513&partnerID=8YFLogxK

U2 - 10.1080/21645515.2019.1627818

DO - 10.1080/21645515.2019.1627818

M3 - Article

C2 - 31216205

AN - SCOPUS:85068503513

SN - 2164-5515

VL - 15

SP - 2865

EP - 2872

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 12

ER -